ArticleJournal of leukocyte biology2002
Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress.
Article in Journal of leukocyte biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 68 citations in OpenAlex.
- Bringing DARC to Light: Role of Duffy Antigen/Receptor in Breast Cancer Progression and Cancer Prevention.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- New pairings and deorphanization among the atypical chemokine receptor family - physiological and clinical relevance.Frontiers in immunology · 2023Review
- Single-cell RNA datasets and bulk RNA datasets analysis demonstratedFrontiers in immunology · 2023Article
- Prospects for targeting ACKR1 in cancer and other diseases.Frontiers in immunology · 2023Review
- The Role of Selected Chemokines and Their Receptors in the Development of Gliomas.International journal of molecular sciences · 2020Review
- Support of Tumor Endothelial Cells by Chemokine Receptors.Frontiers in immunology · 2019Review
- Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury.World journal of gastroenterology · 2017Review
- Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.Advances in wound care · 2015Review
- Lung Angiogenesis Requires CD4(+) Forkhead Homeobox Protein-3(+) Regulatory T Cells.American journal of respiratory cell and molecular biology · 2015Article
- International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Pharmacological reviews · 2014Review
- Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.Mediators of inflammation · 2014Review
- Chemokines in tumor progression and metastasis.Oncotarget · 2013Review
- CXCR2: a target for pancreatic cancer treatment?Expert opinion on therapeutic targets · 2013Review
- Duffy antigen receptor for chemokines and its involvement in patterning and control of inflammatory chemokines.Frontiers in immunology · 2012Article
- Article
- Chemokines in health and disease.Experimental cell research · 2011Review
- Atypical chemokine receptors.Experimental cell research · 2011Review
- Chemokines as mediators of tumor angiogenesis and neovascularization.Experimental cell research · 2011Review
- Platelet-derived chemokines: pathophysiology and therapeutic aspects.Cellular and molecular life sciences : CMLS · 2010Review
- CXC chemokines in cancer angiogenesis and metastases.Advances in cancer research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
CXC chemokines, which induce angiogenesis, have glutamine-leucine-arginine amino acid residues (ELR motif) in the amino terminus and bind CXCR2 and the Duffy antigen chemokine-binding protein. Duffy, a seven transmembrane protein that binds CXC and CC chemokines, has not been shown to couple to trimeric G proteins or to transduce intracellular signals, although it is highly expressed on red blood cells, endothelial cells undergoing neovascularization, and neuronal cells. The binding of chemokines by Duffy could modulate chemokine responses positively or negatively. Positive regulation could come through the presentation of chemokine to functional receptors, and negative regulation could come through Duffy competition with functional chemokine receptors for chemokine binding, thus serving as a decoy receptor. To determine whether Duffy has a role in angiogenesis and/or maintenance of homeostasis, we developed transgenic mice expressing mDuffy under the control of the preproendothelin promoter/enhancer (PPEP), which directs expression of the transgene to the endothelium. Two PPEP-mDuffy-transgenic founders were identified, and expression of the transgene in the endothelium was verified by Northern blot, RT-PCR, and immunostaining of tissues. The phenotype of the mice carrying the transgene appeared normal by all visual parameters. However, careful comparison of transgenic and nontransgenic mice revealed two phenotypic differences: mDuffy-transgenic mice exhibited a diminished angiogenic response to MIP-2 in the corneal micropocket assay, and mDuffy-transgenic mice exhibited enhanced hepatocellular toxicity and necrosis as compared with nontransgenic littermates in response to overdose of acetaminophen (APAP; 400 mg/kg body weight). Morover, APAP treatment was lethal in 50% of the mDuffy-transgenic mice 24 h post challenge, and 100% of the nontransgenic littermates survived this treatment at the 24 h time point. Our data suggest that enhanced expression of mDuffy on endothelial cells can lead to impaired angiogenic response to chemokines and impaired maintenance of homeostasis in response to toxic stresses.
Indexed as
Identifiers
11781390PMC2665273W1902035535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.